MGO One Seven LLC Purchases 443 Shares of IQVIA Holdings Inc. $IQV

MGO One Seven LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 14.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,412 shares of the medical research company’s stock after purchasing an additional 443 shares during the quarter. MGO One Seven LLC’s holdings in IQVIA were worth $538,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in IQV. Brighton Jones LLC raised its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. GAMMA Investing LLC raised its holdings in IQVIA by 56.3% in the first quarter. GAMMA Investing LLC now owns 2,197 shares of the medical research company’s stock worth $387,000 after purchasing an additional 791 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock worth $2,338,000 after purchasing an additional 3,398 shares in the last quarter. Dynamic Advisor Solutions LLC raised its holdings in IQVIA by 20.3% in the first quarter. Dynamic Advisor Solutions LLC now owns 1,770 shares of the medical research company’s stock worth $312,000 after purchasing an additional 299 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in IQVIA by 2.8% in the first quarter. Exchange Traded Concepts LLC now owns 5,357 shares of the medical research company’s stock worth $944,000 after purchasing an additional 148 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $204.51 on Friday. The business’s 50 day moving average price is $191.41 and its 200 day moving average price is $169.23. The firm has a market cap of $34.77 billion, a P/E ratio of 29.60, a P/E/G ratio of 2.26 and a beta of 1.32. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.21. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Mizuho boosted their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Redburn Partners set a $214.00 price target on IQVIA in a research note on Wednesday, September 3rd. Truist Financial boosted their price target on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.